# 2024 Specialty Drug List | California Specialty drugs on the Kaiser Permanente formulary

Specialty drugs are high-cost prescription medications and, in most cases, are used to treat complex chronic conditions such as rheumatoid arthritis, multiple sclerosis, or cancer. Below is a list of the specialty drugs on our formulary, which means they're covered by Kaiser Permanente plans when prescribed by a member's physician as part of a course of treatment.<sup>1</sup>

Most specialty drugs aren't available through mail order because they require special handling such as temperature or storage requirements. A majority of specialty drugs may be limited to a 30-day supply and cannot be mailed.

## The following specialty drugs are on our formulary:<sup>2</sup>

#### **Alcohol Deterrents, Opiate Antagonists**

Vivitrol

#### Anti-infective agents

Ambisome Baraclude Cancidas Cayston Epclusa Harvoni Invanz Livtencity Pegasys Prevymis Sovaldi Synagis Synercid Valcyte Veklury Virazole Vosevi

#### Anti-inflammatory tumor necrosis factor inhibitors

Enbrel

(continues on next page)

## For more information

To see which prescription drugs are on our formulary, go to kp.org/formulary. If you have questions about the specialty drug tier, contact your Kaiser Permanente sales executive or account manager. Members who have questions about their benefits can refer to their Evidence of Coverage. Or they can call our Member Service Contact Center at 800-464-4000 (TTY 711), 24 hours a day, 7 days a week (except holidays).



#### **Antineoplastic agents**

Abraxane Alecensa Alunbrig Arranon Avastin Bendeka Blincyto Brukinsa Cabometyx Calquence Caprelsa Cometriq Copiktra Cosmegen Cotellic Cyramza Dacogen Darzalex Emcvt Enhertu Erbitux Erivedge Gazyva Halaven Herceptin Hycamtin Ibrance Imbruvica Iressa Istodax Ixempra

Jakafi Jevtana Kadcyla Kanjinti Kepivance Keytruda Kisqali Kyprolis Lenvima Lonsurf Lorbrena Lynparza Marqibo Matulane Mekinist Mvasi Myleran Ninlaro Odomzo Oncaspar Opdivo Padcev Perjeta Pomalyst Proleukin Purixan Riabni Rozlytrek Rydapt Sarclisa Sprycel

### Blood formation, coagulation, and thrombosis

Integrilin Praxbind Promacta Leukine Tafinlar Nivestym

**Central nervous system agents** Apokyn

Proglycem

Stivarga

Sylvant

Tafinlar

Tagrisso

Targretin

Tasigna

Taxotere

Tecentriq

Torisel

Treanda

Trisenox

Truxima

Tukysa

Tykerb

Unituxin Velcade

Venclexta

Votrient

Vyxeos

Xalkori

Xtandi

Yervoy

Yondelis

Zanosar

Zelboraf

Zydelig

Zykadia

Zytiga

Zejula

Sabril

#### Chemotherapy rescue/antidote agents

Voraxaze

#### **Cystic fibrosis**

**Cardiovascular drugs** 

Kalydeco Orkambi

Symdeko Trikafta

#### Electrolytic, caloric, and water balance

**Buphenyl** 

#### Enzymes

- Aldurazyme Cerezyme Elaprase Elitek
  - Fabrazyme Lumizyme Naglazyme Pulmozyme

Strensig

Vimizim

Vpriv

#### Eye, ear, nose, and throat preparations

Eylea Lucentis Ozurdex Retisert

#### Gaucher disease

Cerdelga

#### Heavy metal antagonists

Jadenu Chemet Exjade

(continues on next page)



Hemostatics, antihemophilic agents				Parkinson's
Adakveo	Hemlibra			Duopa
Hereditary a		Psoriasis		
Cinryze Firazyr	Haegarda Takhzyro			Otezla
				Respiratory
Hormones and synthetic substitutes				Letairis
Forteo Norditropin Fl	Serostim opin FlexPro Synarel			Remodulin
				Rheumatoi
Immunomod	Kineret			
Actimmune	Vyvgart	Xeljanz		
Metabolic d		Serums		
Cystadane				Hizentra
CystaGane				Skin and m
Miscellaneo	Cosentyx			
Inflectra Ofev	Palforzia Soliris	Ultomiris Xgeva		Kepivance
				Somatostat
Multiple sclerosis				Sandostatin I
Avonex	Tysabri			
Neurologica	l disorders			
Aristada	Inveg	Invega Sustenna		
D · · ·				

**Risperdal Consta** 

s disease ry tract agents Tobi Podhaler Ventavis Tracleer Xolair id arthritis Orencia Hyqvia nucous membrane agents Tremfya Skyrizi Stelara tics

LAR Depot

1. Specialty drugs not listed on Kaiser Permanente's formulary will be covered when prescribed as medically necessary by a Plan provider following the drug formulary exception process. 2. List subject to change. Information may have changed since date of publication.



Briviact